ClinicalTrials.gg
CompletedNCT04984993Updated Sep 21, 2023Results posted

Clinical Investigation Using MED3000 Gel or Tadalafil Tablets in the Treatment of Erectile Dysfunction

A Phase 3 interventional study of MED3000 (Male) and Tadalafil 5mg (Male) in Erectile Dysfunction, sponsored by Futura Medical Developments Ltd.. Completed at 18 sites in 4 countries. Open to male participants aged 22 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by Futura Medical Developments Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
22 Years to 70 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing tadalafil in Erectile Dysfunction — 9 open to participants now, 9 under way, 3 of them phase 3. Tadalafil · Erectile Dysfunction.

Enrollment
37th of 56
116 · median 199
Started
2021
with 1 other
Phase 3
19 of 57
2 open now
Registered
39th of 57
by date

Among the 57 studies testing tadalafil in Erectile Dysfunction, this one is the 37th largest by enrollment of the 56 interventional ones that give a count, is one of 2 that started in 2021, is one of 19 in phase 3, and was the 39th registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

9 of the 57 studies testing tadalafil in Erectile Dysfunction are open now, in 4 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 22 Years to 70 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing tadalafil in Erectile Dysfunction, or all of them as a file.
02

Study summary

An open-label investigation using MED3000 gel or tadalafil (5 mg) tablets in the treatment of erectile dysfunction in patients from 22 to 70 years of age. Each patients will be expected to participate for up to 30 weeks. Eligible patients will be randomised to receive either MED3000 gel or tadalafil (5 mg) tablets in a 1:1 ratio.

03

Conditions studied

  • Erectile Dysfunction

Browse trials for

04

Who can participate

Ages eligible
22 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male heterosexual patients aged 22-70 years.
  • Confirmed clinical diagnosis of mild, moderate or severe ED for more than 3 months.
  • Involved in a continuous heterosexual relationship with their partner for at least 6 months.

Exclusion criteria

Exclusion Criteria:

  • Any significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrinological, metabolic, neurological or psychiatric disease.
  • History of unstable medical or psychiatric condition or using any medication that, in the opinion of the Principal Investigator, is likely to affect the patient's ability to complete the investigation or precludes the patient's participation in the investigation.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    MED3000

    MED3000 gel formulation topically applied to the glans penis

    Device: MED3000 (Male) · Device: MED3000 (Female)

  • Experimental
    Tadalafil

    Tadalafil (5 mg) tablets to be taken orally

    Drug: Tadalafil 5mg (Male) · Drug: Tadalafil 5mg (Female)

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Erectile Function (EF) Domain of the International Index of Erectile Function (IIEF) Questionnaire, in Patients Randomised to MED3000, at Week 24

    Co-primary objectives: * Demonstrate an improvement compared to baseline of erectile function, in patients randomised to receive MED3000, using the IIEF-EF patient reported outcome instrument. * Observe a mean change from baseline of the IIEF-EF, in patients randomised to MED3000, greater or equal to the minimal clinically importance difference of 4. The IIEF is a validated questionnaire, consisting of 15 questions, for detecting treatment changes in EF. The EF domain of IIEF is derived using questions 1, 2, 3, 4, 5 and 15. A score of 0 to 5 is awarded to each of questions 1 to 5 and a score of 1 to 5 is awarded to question 15. Higher scores indicate better sexual function. Domain score is computed by summing the scores for individual questions. The minimum and maximum possible scores are 1 and 30 respectively. Patients with a score of 21 or less are considered to have ED. Change from baseline = Week 24 score - Baseline score.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Percentage of Uses Per Patient That Led to an Onset of Erection Within a Certain Period of Time in Patients Randomised to MED3000.

    Demonstrate a speed of onset of action from application of MED3000 gel to the time when patient notices their erection starting. Percentage of MED3000 uses per patient that resulted in the patient noticing their erection starting within certain period of time, out of the total number of intercourse attempts made using the product during the 24-week treatment period. The certain periods of time are within 15 minutes, 10 minutes and 5 minutes. Percentage of uses is calculated with the denominator equal to the total number of intercourse attempts made using the product during the 24-week treatment period and the numerator equal to the total number of times that the response to the onset of action question 1 indicated a time of 5 (10, 15) minutes or less. Question 1 of the Onset of Action questionnaire: - After application of the gel/taking medication, when did you begin to notice your erection starting?

    Time frame: 24 weeks

  2. Percentage of Uses Per Patient That Led to an Onset of Action Within a Certain Period of Time in Patients Randomised to MED3000.

    Demonstrate a speed of onset of action from application of MED3000 gel to the time when the patients is able to have penetrative sex. Percentage of MED3000 uses per patient that resulted in the patient being able to have penetrative sex within certain period of time, out of the total number of intercourse attempts made using the product during the 24-week treatment period. The certain periods of time are within 15 minutes, 10 minutes and 5 minutes. Percentage of uses is calculated with the denominator equal to the total number of intercourse attempts made using the product during the 24-week treatment period and the numerator equal to the total number of times that the response to the onset of action question 2 indicated a time of 5 (10, 15) minutes or less. Question 2 of the Onset of Action questionnaire: - After application of the gel/taking medication, when were you able to have penetrative sex?

    Time frame: 24 weeks

07

Results

Posted Sep 21, 2023

Participant flow

The first informed consent was on September 14, 2021 and the last study visit was on June 13, 2022.

Participant flow — Overall Study
MilestoneMED3000Tadalafil
Started9696
Received treatment9494
Completed8292
Not completed144
Withdrew: Withdrawal by subject82
Withdrew: Lost to follow-up22
Withdrew: Both patients moved to another country40

Outcome measures

PrimaryChange From Baseline in the Erectile Function (EF) Domain of the International Index of Erectile Function (IIEF) Questionnaire, in Patients Randomised to MED3000, at Week 24

Co-primary objectives: * Demonstrate an improvement compared to baseline of erectile function, in patients randomised to receive MED3000, using the IIEF-EF patient reported outcome instrument. * Observe a mean change from baseline of the IIEF-EF, in patients randomised to MED3000, greater or equal to the minimal clinically importance difference of 4. The IIEF is a validated questionnaire, consisting of 15 questions, for detecting treatment changes in EF. The EF domain of IIEF is derived using questions 1, 2, 3, 4, 5 and 15. A score of 0 to 5 is awarded to each of questions 1 to 5 and a score of 1 to 5 is awarded to question 15. Higher scores indicate better sexual function. Domain score is computed by summing the scores for individual questions. The minimum and maximum possible scores are 1 and 30 respectively. Patients with a score of 21 or less are considered to have ED. Change from baseline = Week 24 score - Baseline score.

Time frame:
Baseline and Week 24
Reported as:
Mean · Score on a scale
Change From Baseline in the Erectile Function (EF) Domain of the International Index of Erectile Function (IIEF) Questionnaire, in Patients Randomised to MED3000, at Week 24
Score on a scaleMED3000
Change From Baseline in the Erectile Function (EF) Domain of the International Index of Erectile Function (IIEF) Questionnaire, in Patients Randomised to MED3000, at Week 245.73 ± 1.00
Statistical analysis
  • MED3000 · t-test, 1 sided · p = <0.001 (Significance level of 0.025)
SecondaryPercentage of Uses Per Patient That Led to an Onset of Erection Within a Certain Period of Time in Patients Randomised to MED3000.

Demonstrate a speed of onset of action from application of MED3000 gel to the time when patient notices their erection starting. Percentage of MED3000 uses per patient that resulted in the patient noticing their erection starting within certain period of time, out of the total number of intercourse attempts made using the product during the 24-week treatment period. The certain periods of time are within 15 minutes, 10 minutes and 5 minutes. Percentage of uses is calculated with the denominator equal to the total number of intercourse attempts made using the product during the 24-week treatment period and the numerator equal to the total number of times that the response to the onset of action question 1 indicated a time of 5 (10, 15) minutes or less. Question 1 of the Onset of Action questionnaire: - After application of the gel/taking medication, when did you begin to notice your erection starting?

Time frame:
24 weeks
Reported as:
Mean · percentage of uses per patient
Percentage of Uses Per Patient That Led to an Onset of Erection Within a Certain Period of Time in Patients Randomised to MED3000.
percentage of uses per patientMED3000
15 minutes62.59 ± 39.18
10 minutes47.81 ± 36.26
5 minutes24.01 ± 33.43
Statistical analysis
  • MED3000 · t-test, 1 sided · p = <0.001 (Significance level of 0.025)
  • MED3000 · t-test, 1 sided · p = <0.001 (Significance level of 0.025)
  • MED3000 · t-test, 1 sided · p = 0.890 (Significance level of 0.025)
SecondaryPercentage of Uses Per Patient That Led to an Onset of Action Within a Certain Period of Time in Patients Randomised to MED3000.

Demonstrate a speed of onset of action from application of MED3000 gel to the time when the patients is able to have penetrative sex. Percentage of MED3000 uses per patient that resulted in the patient being able to have penetrative sex within certain period of time, out of the total number of intercourse attempts made using the product during the 24-week treatment period. The certain periods of time are within 15 minutes, 10 minutes and 5 minutes. Percentage of uses is calculated with the denominator equal to the total number of intercourse attempts made using the product during the 24-week treatment period and the numerator equal to the total number of times that the response to the onset of action question 2 indicated a time of 5 (10, 15) minutes or less. Question 2 of the Onset of Action questionnaire: - After application of the gel/taking medication, when were you able to have penetrative sex?

Time frame:
24 weeks
Reported as:
Mean · percentage of uses per patient
Percentage of Uses Per Patient That Led to an Onset of Action Within a Certain Period of Time in Patients Randomised to MED3000.
percentage of uses per patientMED3000
15 minutes55.70 ± 36.13
10 minutes31.91 ± 29.30
5 minutes13.72 ± 22.33
Statistical analysis
  • MED3000 · t-test, 1 sided · p = <0.001 (Significance level of 0.025)
  • MED3000 · t-test, 1 sided · p = 0.3327 (Significance level of 0.025)
  • MED3000 · t-test, 1 sided · p = >0.999 (Significance level of 0.025)

Adverse events

Collected over 29 Weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MED30000/94 (0%)0/94 (0%)10/47 (21.3%)
Tadalafil0/94 (0%)1/94 (1.1%)16/47 (34%)
Most frequent serious events
Most frequent serious events
EventMED3000Tadalafil
AppendicitisInfections and infestations0/941/94
Most frequent other events
Most frequent other events
EventMED3000Tadalafil
Headache (Male)Nervous system disorders2/479/47
Headache (Female)Nervous system disorders3/470/47
Nausea (Male)Gastrointestinal disorders2/470/47
Non-cardiac chest pain (Male)General disorders0/472/47
Back Pain (Male)Musculoskeletal and connective tissue disorders0/472/47
Abdominal distension (Male)Gastrointestinal disorders1/471/47
Gamma-glutamyltransferase increased (Male)Investigations1/471/47
Pain in extremity (Male)Musculoskeletal and connective tissue disorders1/471/47

Baseline characteristics

Regional enrolment details are combined for both the male participants and their female partners.

Age, Continuous
Age, Continuous(Years)MED3000TadalafilTotal
Male46.1 ± 13.541.5 ± 11.543.8 ± 12.7
Female43.3 ± 13.940.0 ± 11.541.6 ± 12.8
Age, Continuous
Age, Continuous(Years)MED3000TadalafilTotal
Male44.5 (22 to 68)39.0 (23 to 68)40.5 (22 to 68)
Female39.5 (20 to 69)38.0 (19 to 65)39.0 (19 to 69)
Age, Customized
Age, Customized(Participants)MED3000TadalafilTotal
Male — 22-295712
Male — 30-39161834
Male — 40-4951318
Male — 50-5910515
Male — 60-7012517
Male — <22000
Female — 22-2910818
Female — 30-39131831
Female — 40-4931114
Female — 50-5916723
Female — 60-70538
Female — <22112
Sex: Female, Male
Sex: Female, Male(Participants)MED3000TadalafilTotal
Female484896
Male484896
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MED3000TadalafilTotal
Male — Hispanic or Latino000
Male — Not Hispanic or Latino484896
Male — Unknown or Not Reported000
Female — Hispanic or Latino000
Female — Not Hispanic or Latino484896
Female — Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)MED3000TadalafilTotal
United States81018
Poland5256108
Georgia322860
Bulgaria426
Height
Height(cm)MED3000TadalafilTotal
Mean179.20 ± 7.24179.43 ± 7.66179.31 ± 7.41
Height
Height(cm)MED3000TadalafilTotal
Median177.50 (167.0 to 196.0)180.00 (156.0 to 194.0)179.00 (156.0 to 196.0)

5 further baseline measures are reported on the registry.

08

Study locations

18 sites
  • Johns Hopkins University
    Baltimore, Maryland 21205, United States
  • Medical Center "Asklepii"OOD
    Dupnitsa, 2600, Bulgaria
  • ЕТ "Аssoc. Prof. Stefan Popov - Individual Practice for Specialized Outhospital medical care for Neurology and Pscyhiatry"
    Plovdiv, 4002, Bulgaria
  • UMHAT Plovdiv AD
    Plovdiv, Bulgaria
  • MHAT "Silistra"AD
    Silistra, 7500, Bulgaria
  • Medical Center "INTERMEDICA"ООD
    Sofia, 1000, Bulgaria
  • LTD Health
    Batumi, Georgia
  • Jsc "Evex Clinics"
    Kutaisi, 4600, Georgia
  • Rustavi N2 Medical Diagnostic Center
    Rustavi, 3700, Georgia
  • Clinic "GIDMEDI"
    Tbilisi, 0112, Georgia
  • JSC "Evex clinics"
    Tbilisi, 0160, Georgia
  • Raymann LLC
    Tbilisi, 0162, Georgia
  • The Mikolowska Medical Center
    Katowice, 40-065, Poland
  • Provita Sp. z o.o.
    Katowice, 40-611, Poland
  • Medistica Osteomed
    Kraków, 30-074, Poland
  • PROVITA Specialised Gynecology and Sexology Practice
    Lublin, 20-93, Poland
  • Sexology and Pathology of Intercourse Clinic
    Warsaw, 05-077, Poland
  • Ryszard Smoliński's Medical Cabinet
    Wrocław, 53-532, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Jul 2022, 9 months.

Results were first posted in Sep 2023, 1 year 2 months after primary completion.

Of 16 phase 3 interventional studies under Erectile Dysfunction, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 30. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2021
First posted
Aug 2, 2021
StartActual
Sep 14, 2021
Primary completionActual
Jul 13, 2022
CompletionActual
Jul 13, 2022
Results first posted
Sep 21, 2023
Last update
Sep 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04984993
Lead sponsor
Futura Medical Developments Ltd.
Responsible party
Sponsor
First posted
Aug 2, 2021
Start date
Sep 14, 2021
Primary completion
Jul 13, 2022
Completion
Jul 13, 2022
Results posted
Sep 21, 2023
Last update
Sep 21, 2023

Study contacts

Arthur Burnett, MD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion